Core Viewpoint - The debate surrounding the integration of AI in the medical field highlights the contrasting perspectives on its role in enhancing clinical decision-making and training for young doctors, with concerns about the potential impact on clinical thinking and patient care [3][4][5]. Industry Overview - The AI medical sector is evolving, with a focus on knowledge empowerment and clinical evidence support for doctors, which is seen as a more attractive and controversial market compared to patient-facing applications [3][4]. - The number of physicians in China is projected to grow from 3.9 million in 2019 to 5.1 million by 2024, amidst an explosion of medical literature and clinical guidelines, indicating a need for AI to assist in evidence retrieval and alleviate disparities in healthcare resources [3][6]. Company Background - Shanghai Wanyi Medical Technology Co., Ltd. (Wanyi Medical) was founded in 2007 as a medical conference planning company and has transitioned into an AI medical solutions provider, launching the MedEvidence platform aimed at healthcare professionals [4][5]. - The company rebranded from "Wanyi Exhibition" to "Wanyi Medical" in 2020, seeking digital transformation due to the impact of the pandemic on in-person events [5][6]. Financial Performance - Wanyi Medical reported revenues of 239 million RMB and 271 million RMB for 2023 and 2024, respectively, with profits of 29.87 million RMB and 29.72 million RMB [10][11]. - The revenue structure is split approximately 50% between traditional academic event solutions (MedEvent) and digital education solutions (MedAssistant), with the latter's share increasing to 50.4% in the first nine months of 2025 [12][13]. Market Dynamics - The market for academic, educational, and research solutions in medicine is expected to grow from 66.8 billion RMB in 2019 to 97.6 billion RMB by 2024, with a compound annual growth rate (CAGR) of 7.9%, and the AI-driven segment projected to grow at a CAGR of 34.8% from 2024 to 2030 [9][10]. - Despite the promising market growth, Wanyi Medical's AI platform, MedEvidence, has not yet generated revenue, indicating that its AI capabilities are still in the early stages of commercialization [10][14]. Competitive Landscape - Wanyi Medical positions itself in a fragmented market, claiming a leading advantage with nearly 300 million RMB in revenue, while its competitors primarily focus on digital services rather than AI-driven solutions [17][18]. - The company faces significant competition from larger internet firms that have more resources and technological capabilities, which could undermine Wanyi Medical's efforts to establish a strong foothold in the AI medical sector [22][23].

Core Viewpoint - Shanghai Wanyi Medical Technology Co., Ltd. (Wanyi Medical) has submitted a listing application to the Hong Kong Stock Exchange, with Everbright Securities International as the exclusive sponsor [1]. Company Overview - Wanyi Medical is a leading AI-driven solution provider in mainland China, focusing on empowering physician talent development. According to Frost & Sullivan, the company ranks first in the comprehensive AI solution market for medical academia, education, and research in mainland China as of 2024 [3]. - The company has developed an ecosystem connecting physicians and various healthcare participants to accelerate the dissemination of medical knowledge, enhance physician education, and promote the application of research outcomes [3]. Product and Service Offerings - The company primarily offers two AI-driven revenue-generating solutions through its intelligent productivity tools: 1. A full-process solution for medical academic activities delivered via the MedEvent platform, aimed at facilitating workflow coordination and academic exchange among physicians. 2. Digital solutions for medical learning and education, featuring an interactive learning suite developed through the MedAssistant system, tailored to physicians' specialties, interests, and development goals [4]. - Wanyi Medical's clients include medical societies/associations, academic organizations, pharmaceutical, and medical device companies. The company delivers solutions on a project-based model [4]. Financial Performance - The company has experienced revenue growth and profitability during the reporting period: - Total revenue increased from RMB 238.8 million in 2023 to RMB 271.1 million in 2024, and from RMB 177.8 million for the nine months ending September 30, 2024, to RMB 190.7 million for the nine months ending September 30, 2025 [6][10]. - Net profit figures for the same periods were RMB 29.9 million, RMB 29.7 million, RMB 17.7 million, and RMB 36.9 million, respectively [6]. - The company's profit margins were 12.5%, 11.0%, 9.9%, and 19.3% for the years 2023, 2024, and the nine-month periods ending September 30 for 2024 and 2025 [6]. Shareholder Structure - According to the prospectus, Ms. Ju Yue is the controlling shareholder due to her direct interests in the company and her control over the employee incentive platform [7].

Core Viewpoint - Shanghai Wanyi Medical Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Everbright Securities International as its sole sponsor [1]. Company Overview - Wanyi Medical is a leading AI-driven solution provider in China, focused on empowering physician talent development. It ranks first in the comprehensive AI solution market for medical academia, education, and research in China, according to Frost & Sullivan [4]. - The company has developed an ecosystem connecting physicians and various healthcare participants to accelerate the dissemination of medical knowledge, enhance physician education, and promote the application of research outcomes [4]. - Wanyi Medical offers two main AI-driven revenue-generating solutions: (i) a full-process solution for medical academic activities delivered through the MedEvent platform, and (ii) digital solutions for medical learning and education featuring interactive learning kits tailored to physicians' specialties, interests, and development goals [4]. - The company has launched MedEvidence, a suite of intelligent tools including an AI evidence-based assistant to support end-to-end physician-led research processes, enhancing product functionality and physician engagement [4]. Financial Information - For the fiscal years ending September 30, 2023, 2024, and 2025, the company reported revenues of approximately RMB 239 million, RMB 271 million, and RMB 191 million, respectively [5]. - The annual profits for the same periods were approximately RMB 29.87 million, RMB 29.72 million, and RMB 36.88 million [6]. - The gross profit margins for the fiscal years were recorded at 37.9%, 35.7%, and 42.3% [8]. Market Insights - The market for medical academic, education, and research solutions in China is projected to grow from RMB 66.8 billion in 2019 to RMB 97.6 billion in 2024, with a compound annual growth rate (CAGR) of 7.9%. By 2030, the market size is expected to reach RMB 179.5 billion, with a CAGR of 10.7% from 2024 to 2030 [10]. - The market for comprehensive AI solutions in medical academia, education, and research is expected to grow from RMB 0.9 billion in 2019 to RMB 5.7 billion in 2024, with a CAGR of 45.2%. By 2030, the market is projected to reach RMB 33.9 billion, with a CAGR of 34.8% from 2024 to 2030 [13].

的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監會」）的要求而刊發， 僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣下知悉、 接納並向本公司、其保薦人、聯席整體協調人、顧問或包銷團成員表示同意： 本公司招股章程根據香港法例第32章《公 司（清 盤 及 雜 項 條 文）條 例》與 香 港 公 司 註 冊 處 處 長 登 記 前，本 公 司 不 會 向 香 港 公 眾 人 士 提 出 要 約 或 邀 請。倘 於 適 當 時 候 向 香 港 公 眾 人 士 提 出 要 約 或 邀 請，準 投 資 者 務 請 僅 依 據 呈 交 香 港 公 司 註 冊 處 登 記 的 本 公 司 招 股 章 程 作 出 投 資 決 定；有 關 文 本 將 於 發 售 期 內 向 公 眾 刊 發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本文件中的資料 作出任何投資決定； (b) 在聯交所網站登載本文件或其補充、修訂或更換附頁，並不引起本公司、其任何保薦人 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Healife Group Co., Ltd. 上海萬怡醫學科技股份有限公司 (the "Company") (A joint stock limited company incorporated in the People's ...